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ABSTRACT 
Fibroblast growth factors are polypeptide members of the FGF family, which to date 
comprises of at least 22 members. They belong to a group of growth factors and are involved in a 
variety of cellular processes including wound healing, angiogenesis, differentiation and 
development (organogenesis). Amongst FGF members, human acidic FGF-1 and basic FGF-2 
are the most characterized. FGF-1 and FGF-2 are known to share more than 80% sequence 
similarity and have an identical structural fold. However, their biological roles are quite 
different. FGFs bind to heparin and heparan sulfate ligands through their heparin-binding 
pockets. The interactions are primarily electrostatic in nature. The heparin-binding pocket of the 
protein is significant in the interaction of protein with heparin. Therefore, it is important to 
characterize the heparin-binding pocket. This research project focuses on the characterization of 
heparin-binding pocket peptide of FGF1, located at the C-terminal of FGF1 (25 amino acids). To 
achieve this objective a fusion protein was initially created with the FGF1 C-terminal peptide 
fused to Rubredoxin (Rub) protein. The fused protein was expressed in BL21 (DE3) cells and 
purified using affinity chromatography. The FGF1 C-terminal heparin binding peptide (FGF1) 
was then generated by thrombin cleavage of the fused peptide and characterized by Circular 
Dichroism (CD), Fluorescence and Mass Spectroscopy. Characterizing the C-terminal heparin-
binding region of FGF1 will aid in the understanding of the interactions involved between FGF1 
and Fibroblast Growth Factor Receptors and subsequent signal transduction cascades. It will also 
assist in the development of agonists and antagonists of FGF1 that could potentially be used to 
regulate various cellular processes, both physiological and pathological. In addition, it could help 
in understanding the interaction of heparin with other proteins that contain the heparin-binding 
pocket.  
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A. INTRODUCTION 
Fibroblast growth factors (FGFs) are multifunctional polypeptide effectors, which interact 
with transmembrane tyrosine kinase receptors referred to as Fibroblast growth factor receptors 
(FGFRs) (Mohammadi, Olsen, & Ibrahimi, 2005). This interaction is mediated by heparin or 
heparin sulfate (HS). FGF-FGFR interaction and subsequent signal transduction result in the 
regulation of various cellular responses including embryonic development, adult tissue 
homeostasis, regenerative processes and associated tissue-specific pathologies (Kan, Wang, To, 
Gabriel, & McKeehan, 1996; Mohammadi et al., 2005). 
More than 200 human heparin-interacting proteins have been identified to date (Ori, Free, 
Courty, Wilkinson, & Fernig, 2009). FGF is one of them. The structural features mediating the 
interactions of heparin with various proteins is an area of active research. In general, all 23 FGFs 
consist of 150-300 amino acids and their molecular weight is in the range 16-34-kDa (Belov & 
Mohammadi, 2013; Pellegrini et al., 2000). Members of the fibroblast growth factor (FGF) 
family of polypeptides are ubiquitous bioregulators within tissues (Kan et al., 1996). Their 
activity is regulated by heparan sulfates in the pericellular matrix (Kan et al., 1996).  
Fibroblast growth factors (FGF) are secreted signaling proteins with diverse biological 
activities including embryonic development, angiogenesis, wound healing, nerve regeneration, 
chronic inflammation and cancer (Ornitz & Itoh, 2015). Till date 22 members have been 
identified (FGF-1 to 14 and FGF-16 to 23) (Itoh, 2007). These are further sub-divided into six 
sub-families. FGFs modulate proliferation and differentiation of a variety of mesenchymal and 
neuroectodermal cells (Bellosta et al., 2001) . They also play critical roles during numerous 
embryonic process including mesoderm induction, limb and lung development and blastocyst 
development (Bellosta et al., 2001). According to literature, a number of human skeletal 
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disorders, for instance, dwarfism result as a consequence of increased FGF signaling (Bellosta et 
al., 2001). The major role of FGFs is in wound healing and physiological and pathological 
angiogenesis (Bellosta et al., 2001).  
FGFs, in contrast to other growth factors bind heparin or extracellular heparin sulfate 
proteoglycan (HSPG) to activate FGFRs and have a homologous central core of 140 amino acids 
(Woodbury & Ikezu, 2014).  
1. HS and HSGAGs 
Extracellular complex polysaccharides such as heparin, heparin sulfate (HS) and heparan 
sulfate glucosaminoglycans (HSGAGs) have important roles in developmental biology and 
cancer biology (Raman et al., 2003). These HSGAGs bind morphogens, growth factors and 
enzymes in a sequence-specific manner and result in influencing the physiological state of cells 
and tissues (Raman et al., 2003). They are necessary components for growth factor binding to its 
receptors leading to a biological response: development, inflammation, immune response and 
disease (Bellosta et al., 2001). Therefore, it is essential to understand how HSGAG-protein 
sequence-specific interactions result in important signaling cascades such as FGF-FGFR 
signaling (Raman et al., 2003). HSGAG regulates FGF signaling differentially via the cell 
surface tyrosine kinase receptors (FGFR).  
HS is essential for the normal functioning of a number of developmental pathways 
including: FGF, Wingless/Wnt, Dpp (decapentaplegic)/BMP (bone morphogenetic protein) and 
Hedgehog as revealed by genetic studies carried out in different model organisms including 
Drosophila (Kreuger et al., 2005). Enzymes involved in HS biosynthesis result in abnormal 
distribution and signaling of these growth factors and morphogens if defective/mutated (Kreuger 
et al., 2005).  
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HSGAGs as shown in Figure A1 mediate FGF binding to FGFRs, generating a ternary  
complex that is required for downstream signaling (Venkataraman, Shriver, Davis, & 
Sasisekharan, 1999). FGFs interact with the sulfated domains of heparin sulfates (HS) moieties 
of cell surface and extracellular matrix-associated heparan sulfate proteoglycans (HSPGs) 
(Ostrovsky et al., 2002). They also interact with heparin, which is a highly sulfated 
polysaccharide that shares structural similarity with heparan sulfates and can therefore mimic 
their action (Ostrovsky et al., 2002). These molecules protect FGFs from heat inactivation and 
proteolytic degradation and provide an extracellular reservoir from which FGFs can be rapidly 
released (Ostrovsky et al., 2002).  
 
According to the Figure A1, HSGAGs are linear polysaccharides, which are 
characterized by a disaccharide repeat unit of a-D-glucosamine (1→4) linked to pyranosyluronic 
acid (Muñoz & Linhardt, 2004; Raman et al., 2003).  An acetyl or sulfo group may be substituted 
Figure A1. FGF-HSGAG structural complex. (A) 
HSGAG oligosaccharide chemical structure. (B) 𝛽-
trefoil scaffold of FGF and the orientation of HSGAG 
oligosaccharide as shown by dotted-green circle. 
(Raman, Venkataraman, Ernst, Sasisekharan, & 
Sasisekharan, 2003) 
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at the amino group of the glucosamine residue (Raman et al., 2003). HS, like HSGAG is also a 
linear copolymer of uronic acid 1→4 linked to glucosamine, but unlike HSGAG has a more 
varied structure and is less substituted in sulfo groups than heparin (Kreuger et al., 2005; Muñoz 
& Linhardt, 2004). D-glucuronic acid predominates in HS, although substantial amounts of L-
iduronic acid can be present (Muñoz & Linhardt, 2004). The glucuronic acid composed 
precursor HS is modified partially through a series of reactions involving N-deacetylation and N-
sulfation, etc (Kreuger et al., 2005). These reactions are variably regulated in different cells and 
tissues and also at different developmental stages, therefore, the modified mature HS is shown to 
contain sulfated domains of variable length and composition (Esko & Lindahl, 2001; Gallagher, 
2001). These domains are important because they provide binding sites for protein ligands 
(Kreuger et al., 2005). 
The interactions between FGF and HSGAG are predominantly ionic, with van der Waal 
forces also influencing the FGF-HSGAG binding (Raman et al., 2003). Upon FGF binding, a 
kink is introduced in the helix axis of HSGAG (Raman et al., 2003). In addition, the spatial 
distribution of basic residues in the protein is another structural feature that facilitate interaction 
between HSGAG and FGF (Raman et al., 2003). These basic residues interact with the sulfate 
groups in the interacting HSGAG chain (Raman et al., 2003). The FGF-HSGAG structural 
complex is shown in Figure A1.  
Figure A1 (B) shows the 𝛽-trefoil scaffold of FGF and the orientation and chain direction 
of the HSGAG oligosaccharide relative to the sheets shown (S1, S2, and S3). The dark blue 
regions in the loops represent the basic residues that the oligosaccharides (shown by the green 
circle) interact with (Raman et al., 2003).  
FGF members bound to heparin have been shown to exhibit increased stability in the 
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presence of acid, heat, mild oxidation, and proteolysis (DiGabriele et al., 1998) . This is 
significant, since human FGF1, in the absence of sugar poly anions, tends to unfold at 
physiological temperature (Blaber, DiSalvo, & Thomas, 1996; Yeh et al., 2002).  
2. Heparin and Heparin-binding pocket 
Heparin is the most widely used anticoagulant (Muñoz & Linhardt, 2004). Heparin is 
primarily intracellular, whereas HSGAG are common components of cell surface and 
extracellular matrix (Muñoz & Linhardt, 2004). Heparin binds to numerous proteins including 
proteases, growth factors, chemokines, lipid-binding proteins and pathogen proteins (Muñoz & 
Linhardt, 2004).  
Heparin is negatively charged due to sulfo and carboxyl groups present in the 
disaccharide (Muñoz & Linhardt, 2004). This is why the interaction of heparin with other 
proteins is ionic in nature. The heparin-binding pockets in proteins are characterized by the 
presence of positively charged amino acids (Muñoz & Linhardt, 2004). Hydrogen bonding and 
hydrophobic interactions also contribute to the stability of heparin-protein complexes (Muñoz & 
Linhardt, 2004). The interaction of heparin and protein is sequence-specific (Muñoz & Linhardt, 
2004). A consensus sequence exists in the heparin-binding pocket of proteins that is necessary 
for the generation of heparin-protein complex with appropriate affinity and specificity (Blaber et 
al., 1996; Muñoz & Linhardt, 2004).  
The most frequent residues present in the heparin- and heparan sulfate (HS)-binding 
proteins are arginine and lysine (Muñoz & Linhardt, 2004). Arginines bind more tightly as 
compared to lysines, even though both carry a positive charge at physiological pH. This is 
because arginine forms stable hydrogen bonds and stronger electrostatic interactions with sulfo 
groups present in heparin and HS (Muñoz & Linhardt, 2004). Serine and glycine are some non-
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basic residues that are also known to play a role in heparin-protein interactions because their 
smaller side-chains, thereby providing more flexibility and less steric constraints (Muñoz & 
Linhardt, 2004). 
In order to determine the critical amino acids and their spatial arrangement in heparin-
binding proteins like FGF and to identify the consensus sequence present in heparin-binding 
pocket of heparin-binding proteins, the 3D protein structure and the structure of heparin-binding 
site needs to be established. This can be done through X-ray crystallography, which provides 
high-resolution structural information about the protein complexes. The structure of heparin in 
complex with fibroblast growth factors (FGFs) is present (Muñoz & Linhardt, 2004). The 
analysis of the heparin-protein complex can reveal the residues present in the heparin-binding 
pocket by the proximity of basic amino acids to negatively charged groups in heparin. In order to 
determine the significance of each residue involved in binding, side-directed mutagenesis of the 
wild-type protein can be carried out. Detailed characterization of heparin-binding sites on 
proteins can be obtained by carrying out binding studies and biological activity assays. Affinity 
chromatography is one the most commonly used techniques to study the binding affinity of 
heparin-protein interactions (Muñoz & Linhardt, 2004). Understanding the interactions of 
heparin with proteins at the molecular level will help in improved understanding of designing 
therapeutic drugs that can be employed in disease and pathology.  
A specific region of FGF molecule interacts with FGF receptors and heparin (Ornitz & 
Itoh, 2001). The receptor-binding site is contiguous with the heparin-binding site. This region is 
located at loop 3/hairpin 3 segment of human acidic FGF (FGF-1) (Ornitz & Itoh, 2001). This 
region is used commonly as a model for the design of peptide-based agonists/antagonists of the 
FGFs (Ornitz & Itoh, 2001).  
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3. Heparin-binding Domains of FGF1 
Heparin potentiates the mitogenic activity of FGF-1 and protects it from proteolysis 
(trypsin digestion) and heat inactivation (Wong et al., 1995). Binding to heparin increases FGF 
stability under oxidizing conditions (low pH and higher temperatures) (Pineda-Lucena et al., 
1994).  It also increases the apparent affinity of FGF-1 for FGFRs (Wong et al., 1995). 
Identification of the heparin-binding domain of FGF1 was therefore significant and aided in the 
development of peptide-based antagonists of its function (Wong et al., 1995).  
A number of consensus sequences of the heparin-binding regions in heparin-binding 
proteins were proposed and included the motifs XBBXBX and XBBBXXBX, where B and X are 
basic amino acid and hydropathic residue, respectively (Wong et al., 1995). FGF1 amino acid 
sequence was analyzed and it revealed the presence of three regions including residues 22-27, 
113-120 and 124-131 that is in agreement with the proposed consensus sequences (Wong et al., 
1995). The affinity of recombinant FGF1 for heparin is reduced when lysine 132 in FGF1 is 
mutated to a glutamic acid (K132E) or glycine (K132G) by side-directed mutagenesis, even 
though lysine 132 lies outside the regions of FGF1 residues proposed (Wong et al., 1995). This 
was determined using affinity chromatography. The mutant still binds and activates FGFRs and 
transcribes a variety of immediate-early genes (Wong et al., 1995). Changing lysine 23, 24, or 26 
to glycine does not alter the affinity of the mutants to heparin binding, whereas there was minor 
reduction when residues 113-120 were modified (Wong et al., 1995). On the other hand, 
mutating residues in the third proposed region 124-131 had significant and varying effects on 
heparin binding (Wong et al., 1995). The reduction in the binding affinities of most of the mutant 
proteins (124-131) was mostly due to change in mutants protein folding and stability (Wong et 
al., 1995). The binding affinities were observed in the presence of exogenous heparin, so that 
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binding to cell surface HSPGs was inhibited (Wong et al., 1995). 
A more stringent analysis of the heparin-binding pocket of FGF1 revealed that basic 
residues 126 and 133 are crucial to heparin binding (Wong et al., 1995). These residues satisfied 
the spatial requirement of basic amino acids at opposite ends of a beta-strand fold (Wong et al., 
1995). 
Mutations in the heparin-binding regions of FGF1 and FGF2 have resulted in reduced 
mitogenic activities (Mohammadi et al., 2005). Heparin and HS are proposed to not only 
stabilize and protect FGF from heat and proteolysis degradation, they also facilitate the 
interaction of FGFs with FGFRs by inducing a conformational change in the tertiary structure of 
FGF and act as storage reservoirs where FGF can be liberated for interaction with FGFR 
(Mohammadi et al., 2005). Genetic studies in mice and flies have also shown that HS is required 
for FGF signaling in whole organisms (Mohammadi et al., 2005). Since binding of heparin and 
heparin sulfates is the primary step in the formation of FGF-FGFR-heparin ternary complex and 
is absolutely required for FGF signaling; characterizing the heparin-binding region of FGF is 
necessary and significant.  
4. Broad function of FGF 
FGFs play an important role in the regulation of proliferation and differentiation in stem 
cells: embryonic stem cells, Trophoblast stem cells and neural stem cells. They also play 
important roles in development and morphogenesis (Venkataraman et al., 1999). Members of the 
FGF family function in the earliest stages of embryonic development and also during 
organogenesis in order to maintain progenitor cells and mediate their growth, differentiation, 
survival and patterning (Ornitz & Itoh, 2015). In adult tissues FGFs are involved in the 
mediation of metabolic functions, tissue repair, regeneration, and also reactivate some 
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developmental signaling pathways (Ornitz & Itoh, 2015). They are also involved in tissue repair 
and activate appropriate signaling pathways in response to injury (Ornitz & Itoh, 2015).  
The regulation of differentiation of the inner mass cells (IMCs) into the epiblast and 
primitive endoderm lineages in regulated by FGFs during early development (Ornitz & Itoh, 
2015). During later developmental stages, FGFs are involved in organogenesis, which includes 
the regulation of anterior and secondary heart fields, induction of limb and lung buds, liver, 
pancreas, kidney and brain development (Ornitz & Itoh, 2015).  
5. FGF-Receptor- The Chemistry and Structure 
The various biological processes regulated by FGFs require spatial and temporal 
integration of several cell responses, including cell survival, proliferation, migration and 
invasion, and cell differentiation (Bellosta et al., 2001). These diverse effects of FGFs are 
mediated by four tyrosine kinase receptors of ~800 amino acids, FGF receptors (FGFR-1 to 4) 
(Bellosta et al., 2001). Fibroblast growth factor receptors (FGFRs) are located on cell surface 
membranes (Kan et al., 1996).  
Figure A2 represents the FGFR protein structure (Ornitz & Itoh, 2015).  The figure also 
represents the splice variants of FGFR proteins. FGFR1-3 generate two splice variants of Ig-like 
domain III, (IIIb and IIIc) (Ornitz & Itoh, 2015).  These major variants are essential ligand-
binding specificity determinants (Ornitz & Itoh, 2015).   
The tyrosine kinase domain located in the cytoplasmic part. The cytoplasmic domain also 
contains extra regulatory sequences (Ornitz & Itoh, 2015).  These receptors share common 
features, which include an extracellular ligand-binding domain, a transmembrane domain and a 
conserved cytoplasmic tyrosine kinase domain (Bellosta et al., 2001; Bikfalvi, Klein, Pintucci, & 
Rifkin, 1997; Ornitz & Itoh, 2015).  The extracellular ligand-binding domain contains 
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immunoglobulin-like domains D1-D3 (Bellosta et al., 2001; Bikfalvi et al., 1997). Several 
isoforms of FGFRs exist because of alternating splicing of D1-D3 immunoglobulin domains of 
RTKs as shown in Figure (Ornitz & Itoh, 2015).  There is an acid box region containing 7-8 
acidic residues in between D1 and D2 (Bellosta et al., 2001; Ornitz & Itoh, 2015).  The ligand-
binding domain is located specifically between D2 and D3 and the short D2-D3 linker (Bellosta 
et al., 2001).  
 
The FGFR receptor families are conserved in humans, Drosophila, C. elegans, etc 
(Bikfalvi et al., 1997). Mutations in the FGFR can lead to abnormal morphogenesis, and the 
progression of several types of cancers (Ornitz & Itoh, 2015).   
6. Classification of each form of FGF 
The fibroblast growth factor family presently has 23 members (Ornitz & Itoh, 2015).  
Each of these members has HSGAG-binding domain that varies from member to member 
(Raman et al., 2003). The members of the FGF family can be found in different organisms from 
nematodes to humans (Belov & Mohammadi, 2013). Homology and phylogenetic studies reveal 
Figure A2. Schematic representations of FGFR protein 
structures. The figure represents three extracellular 
immunoglobulin-like domains (I, II, and III), a transmembrane 
domain (TM), and two intracellular tyrosine kinase domains 
(TK1 and TK2). SP-cleavable secreted signal sequence. (Ornitz 
& Itoh, 2015) 
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that these members are grouped into seven sub-families as shown in Figure A3 (Ornitz & Itoh, 
2015).   
 
The families are characterized based on their function, sequence similarity and mode of 
signaling (Belov & Mohammadi, 2013). Members of the FGF family are related by core 
sequence and structure conservation and are found in both vertebrates and invertebrates (Ornitz 
& Itoh, 2015).  The first five subfamilies are involved in paracrine signaling (acts locally) and 
the sixth subfamily (FGF19, 21 and 23) is involved in endocrine signaling (long-distance) 
(Pellegrini et al., 2000). In general, secreted FGFs function as autocrine or paracrine factors 
(canonical FGFs), whereas FGF19, 21 and 23 (three members of the secreted FGFs) have 
evolved to function as endocrine factors (Ornitz & Itoh, 2015).  Endocrine FGFs regulate 
Figure A3. FGF families. According to phylogenetic 
analysis, 22 members of FGF are categorized in seven 
subfamilies. The branch lengths represented in this 
figure are proportional to the evolutionary distance 
between each gene member. (Ornitz & Itoh, 2015) 
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phosphate, bile acid, carbohydrate and lipid metabolism in adults, whereas paracrine FGFs 
control cell proliferation, differentiation and survival (Ornitz & Itoh, 2015).   
The human FGF genes are expressed at different unique sites and are expressed 
differentially in tissues (Ornitz & Itoh, 2015).  For instance, FGF 3, 4, 8, 15, 17, and 19 are 
expressed during embryonic development (Belov & Mohammadi, 2013). FGF 1, 2, 5, 6, 7, 9-14, 
16, 18, 20-23 are expressed in embryonic and adult tissues (Belov & Mohammadi, 2013). Except 
FGF16, the gene locations of all 22 FGF genes are known. The gene locations are various for all 
human FGF genes; they are created through chromosomal events such as translocation and 
chromosomal duplication (Belov & Mohammadi, 2013). 
Seven FGF subfamilies as represented in Figure A3 ((Ornitz & Itoh, 2015).  
I. FGF1 Subfamily (FGF1 and FGF2) 
 FGF1 and FGF2 belong to FGF1 subfamily and lack classical secretory signal peptides 
(Ornitz & Itoh, 2015).  However, they can be exported out from the cells directly by 
translocation across the cell membrane (Ornitz & Itoh, 2015).  A chaperone complex that 
includes synaptotagmin-1 and calcium-binding protein (S100A13) is involved in translocation 
(Ornitz & Itoh, 2015).  Both FGF1 and FGF2 have also been found in the nucleus (Ornitz & Itoh, 
2015).   
a. Acidic FGF (FGF1) 
Human acidic FGF (FGF1) is a 16-kDa polypeptide, which was purified from brain 
originally (Pineda-Lucena et al., 1994). The crystal structure of FGF1 reveals that it consists of 
twelve antiparallel B strands (Pellegrini et al., 2000). Six beta-strand pairs within the beta-trefoil 
fold at the base of three of the strand pairs create a beta-barrel (Pellegrini et al., 2000). In 
addition, five of the pairs are designed as a hairpin structure (Pellegrini et al., 2000).  
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b. Basic FGF (FGF2) 
Human Basic FGF (FGF2) has pleiotropic effects in different tissues and organs, and has 
a role in angiogenesis, differentiation and the function of the central nervous system (CNS) 
(Bikfalvi et al., 1997; Woodbury & Ikezu, 2014). Five different polypeptides can be formed from 
the same FGF2 gene via five different mRNA translation initiation sites (Woodbury & Ikezu, 
2014). FGF2 is an established neurogenic factor for proliferation and differentiation of 
multipotent neural stem cells during development (Bikfalvi et al., 1997; Woodbury & Ikezu, 
2014). It is also a potent angiogenic molecule, which is known to stimulate smooth muscle 
growth, wound healing and tissue repair in vitro as well as in vivo (Bikfalvi et al., 1997).  
FGF-2 was initially isolated from pituitary gland and was identified as a 146-amino acid 
protein (Bikfalvi et al., 1997; Pineda-Lucena et al., 1994). It is closely related (55% similarity) to 
FGF1 (Pineda-Lucena et al., 1994).  
The structure of FGF-2 reveals the presence of 12 anti-parallel beta-sheets, which are 
organized into a trigonal pyramidal structure (Bikfalvi et al., 1997). The receptor-binding sites 
are located between the residues 13-30 and 106-129 (Bikfalvi et al., 1997).  
II. FGF4 Subfamily (FGF4, FGF5, FGF6) 
Members of the FGF4 subfamily are secreted proteins and have cleavable N-terminal 
signal peptides (Ornitz & Itoh, 2015).  FGF4, unlike FGF1 and FGF2 has a classical signal 
peptide and is secreted from cells efficiently (Bellosta et al., 2001). Members of this subfamily 
activate IIIc splice variants of FGFRs 1-3 as shown in Figure A2 and FGFR4 (Ornitz & Itoh, 
2015).   
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III. FGF7 Subfamily (FGF3, FGF7, FGF10, FGF22) 
Members of this subfamily of proteins activate the IIIb splice variant of FGFR2, 
preferentially (Ornitz & Itoh, 2015).  FGF3 and FGF10 are also known to activate the IIIb splice 
variant of FGFR1 (Ornitz & Itoh, 2015).   
IV. FGF8 Subfamily (FGF8, FGF17, FGF18) 
Members of this family, like the FGF4 subfamily also contain an N-terminal cleavable signal 
peptide and activate IIIc splice variants of FGFRs 1-3 and FGFR4 (Ornitz & Itoh, 2015).   
V. FGF9 Subfamily (FGF9, FGF16, FGF20) 
FGF9, 16 and 20 do not have an N-terminal cleavable signal peptide, but they have an 
internal hydrophobic sequence (Ornitz & Itoh, 2015).  This sequence facilitates in the transport 
of these FGFs into the endoplasmic reticulum (ER) and secretion from cells (Ornitz & Itoh, 
2015).  They also activate the IIIc splice variants of FGFRs 1-3 and FGFR 2, like members of 
FGF4 and FGF8 subfamily, in addition to IIIb splice variant of FGFR3 (Ornitz & Itoh, 2015).   
VI. FGF15/19 Subfamily (FGF19, FGF21, FGF23) 
FGF-19 subfamily members include FGF-19 (the human ortholog of mouse FGF-15), FGF-
21 and FGF-23 (Pellegrini et al., 2000). Members of this subfamily are endocrine FGFs (Ornitz 
& Itoh, 2015). The affinity of these FGFs to heparin is weak, and therefore require cofactors; 
members of the Klotho family, for receptor binding and subsequent activation (Ornitz & Itoh, 
2015). This aids in the release of FGFs from ECMs (Ornitz & Itoh, 2015).   
VII. FGF11 Subfamily (FGF11-14) 
FGF 11-14 are intracellular FGFs (Ornitz & Itoh, 2015). FGF-11 to 14 are members of the 
FGF-11 subfamily and are also known as fibroblast growth factor-homologous factors (FHFs). 
They have high sequence and structural homology with FGFs and bind HSPG with high affinity. 
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Generally, they are not considered as members of the FGF family. This is because they do not 
activate FGFRs, most likely due to structural incompatibility of the FGFR-interacting region. 
FHFs act as intracellular signaling molecules via interaction with islet brain-2 scaffold protein 
and cytoplasmic carboxy terminal tail of voltage-gated sodium channels (Ornitz & Itoh, 2015).  
The receptor specificity of all subfamilies of FGFs for FGFRs is summarized in the Table 
A1. 
 
7. FGF Signaling process 
The binding of FGF and HSPG to the extracellular ligand domain of FGFR induces 
receptor dimerization, activation and auto-phosphorylation of multiple tyrosine residues in the 
cytoplasmic domain of the receptor molecule (Mohammadi et al., 2005). When FGF-heparin 
complex binds to the D2-D3 region of the FGFR, the receptor dimerizes. This leads to auto- 
phosphorylation of seven tyrosines in the protein tyrosine kinase (PTK) domain of the FGFR, 
Table A1. Receptor specificity of canonical and 
endocrine FGFs. Table adapted from (Ornitz & Itoh, 
2015).  
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activating various signaling pathways that include RAS-MAPK, PI3K-AKT, PLC-gamma, and 
STAT intracellular signaling pathway (Ornitz & Itoh, 2015).   
FGFR binding specificity is an essential mechanism in the regulation of FGF signaling. 
Autocrine or paracrine FGFs, also known as canonical FGFs are tightly bound to heparin/ 
heparan sulfate (HS) proteoglycans (HSPGs), which tightly regulate the FGF-FGFR signaling 
pathway by limiting the diffusion through the extracellular matrix (ECM) and also by serving as 
cofactors, thereby regulating the specificity and affinity of FGFs for FGFRs (Ornitz & Itoh, 
2015).   
 
Binding of FGF to FGFR tyrosine kinase results in the sequential phosphorylation of six 
tyrosine residues, the phosphorylation of all is required for the full activation of the kinase 
domain (Ornitz & Itoh, 2015). Y653 is initially phosphorylated, which results in a 50-100-fold 
increase in the tyrosine kinase activity (Ornitz & Itoh, 2015). This is followed by Y583, Y463, 
Y766 and Y585 phosphorylation in that order (Ornitz & Itoh, 2015). In the third and last phase 
of receptor activation, Y654 is phosphorylated, which causes a further ten-fold (500-1000-fold) 
Figure A4. FGF Signaling Pathways. Figure 
adapted from (Ornitz & Itoh, 2015).  
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increase in the activation of the receptor (Muñoz & Linhardt, 2004). Four major intracellular 
signaling pathways are then activated by tyrosine kinase FGFR activation: RAS-MAPK, PI3K-
AKT, PLC-gamma, and signal transducer and activator of transcription (STAT) as shown in 
Figure A4 (Ornitz & Itoh, 2015). Activation of PLC-gamma and STAT3, however requires the 
phosphorylation of two additional tyrosine residues Y677 and Y766 (Ornitz & Itoh, 2015).   
 
8. FGF1-FGFR 
FGF1 is a universal ligand for all FGFRs (1-4) (Bellosta et al., 2001). Most of FGF 
members bind FGFRs promiscuously, although the binding is specific (Bellosta et al., 2001). 
Crystal structures of FGF1-FGFR1, FGF2-FGFR1 and FGF2-FGFR2 complexes were compared 
and it was shown that FGF N-terminal (region immediately adjacent and preceding the beta-
Figure A5. FGF1-FGFR2-Heparin Complex. (a) D2 and D3 
domains of FGFR2 shown in cyan and magenta, respectively. 
FGF1 is green. Heparin molecule is shown in the middle in 
CPK representation. (b) Different representation. (c) Ligand-
binding region of human FGFR2 with cyan and magenta 
regions representing D2 and D3. Boxed regions are secondary 
structures. Figure adapted from (Pellegrini et al., 2000) 
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trefoil core domain of FGF) and central regions of FGFR D3 interact specifically (Bellosta et al., 
2001; Plotnikov, Hubbard, Schlessinger, & Mohammadi, 2000). There is a general binding  
interface for FGF-FGFR complexes; where FGF makes contacts with D2 of FGFR and D2-D3 
linker as shown in Figure A5 (Bellosta et al., 2001; Plotnikov et al., 2000). The crystal structure 
of FGF1-FGFR2-heparin ternary complex reveals that the heparin molecule links the two FGF 
ligands into a dimer, which subsequently acts as a bridge between two FGFR2 receptor chains 
(Bellosta et al., 2001).   
 
Literature suggests that heparin plays a dual role in the formation of FGF1 signaling 
complexes (Gallagher, 2001; Pellegrini et al., 2000). In addition to mediating interaction between 
FGF1 and FGFR2, it acts as a template for the dimerization of FGF1-FGFR2 subunits 
(Gallagher, 2001; Pellegrini et al., 2000). This is significant because it can allow the study of 
heparin-mediated interaction between other ligands and receptors.   
Figure A6.  Heparin-binding site in FGF1-
FGFR2-heparin ternary complex. Heparin is 
represented as a stick model. The blue regions in 
the space-filling model show the positively 
charged residues that interact with heparin 
disaccharide. Figure adapted from (Pellegrini, 
Burke, von Delft, Mulloy, & Blundell, 2000). 
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The interaction of heparin with FGF1 dimer is shown in Figure A7 generated using 
Pymol. The interaction of FGF1 with FGFR2 is shown in Figure A8 generated using Pymol. 
 
 
Figure A7.  Heparin-linked dimer of Fibroblast Growth Factor 
1. Green cartoon model shows FGF1 and the sticks represent 
heparin. Magenta represents the heparin binding pocket of FGF1 
with sequence GSNWFVGLKKNGSCKRGPRTHYGQK: PDB 
ID: 2AXM. (DiGabriele et al., 1998) 
Figure A8.  Ligand-binding portion of the Fibroblast Growth Receptor 
2 in complex with FGF1. Cyan represents FGFR2 and red represents 
FGF1, with the heparin-binding pocket of FGF1 represented as 
magenta. PDB ID:  1DJS. (Stauber, DiGabriele, & Hendrickson, 2000) 
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9. Application of Basic FGF in medicine 
The involvement of FGF signaling in human disease is well documented. Aberrant FGF 
expression is central to progression of pathogenesis in several disease states, including cancer 
and chronic inflammation (Venkataraman et al., 1999). Because FGFs are present in almost all 
adult tissues and organs, consistent with their roles in development and organogenesis, any 
abnormal activity in the FGF signaling pathway leads to developmental defects that result in the 
disruption of organogenesis, impair the organism’s response to injury, and also result in some 
metabolic disorders (Ornitz & Itoh, 2015). 
10. Rubredoxin (Rub) 
Rubredoxin (Rub) is 6.1-kDa red protein that is isolated from Thermotoga maritime 
(Kohli &   Ostermeier, 2003). It contains an Fe (III)-cysteine4 center and is commonly used as a 
colored fusion tag for the expression of recombinant proteins in E. coli, like green-fluorescent 
protein (GFP) and Flavodoxin (Kohli & Ostermeier, 2003). Rub is known to be stable over a 
wide range of pH, temperature and buffer environments, which facilitates its purification (Kohli 
& Ostermeier, 2003). It is found in bacteria, archaea and plants (Kohli & Ostermeier, 2003). 
Most importantly, it provides a direct on-line readout during chromatography; therefore, we 
employed it in our research project by fusing it to the N-terminal of FGF-peptide. 
Rub is a highly soluble bacterial protein and it offers a unique red color, which is directly 
detectable (Kohli & Ostermeier, 2003). The 3D protein structure of Rubredoxin reveals the 
presence of the fold that belongs to the +beta class, with 2 -helices and 2-3 beta strands (Kohli & 
Ostermeier, 2003). The active site of Rub contains an iron ion coordinated by the sulfurs of four 
conserved cysteine residues, which forms a regular tetrahedron (Kohli & Ostermeier, 2003). 
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11. Scope of my research 
Since many biological processes in humans such as embryonic development, wound 
healing and angiogenesis require FGF-FGFR signal transduction systems; it is essential to 
characterize one of the major components of this signal transduction pathways: the 
characterization of heparin-binding pocket of FGF1 that recognizes the heparin sulfate required 
for FGF1-FGFR interaction. Characterization of heparin-binding pocket peptide of FGF1 will be 
useful to design agonists and antagonists for FGF1 which could potentially be used to treat 
human skeletal disordesrs and block angiogenesis in pathological conditions, for instance, tumor 
neovascularization. 
   FGF1 has broad specificity and is unique among all members of the FGF family because 
it can bind to all seven members of FGF receptor subtypes. Therefore, it is important to 
characterize the heparin-binding pocket of FGF1 because it is a potent mitogen for various cell 
types. Understanding the function of heparin-binding peptide in detail can lead to the 
understanding of FGF1-FGFR interaction and subsequently their roles in diverse biological 
processes. 
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B. MATERIALS AND METHODS 
1. Competent Cells Preparation 
DH5𝛼 competent cells were prepared. 50ml of sterile Luria Broth (LB) was inoculated 
with DH5𝛼 from glycerol stocks available in the lab. Media was incubated overnight at 37℃ at 
250rpm for 12-16 hours. 500ml autoclaved LB was sub-cultured with 1% primary culture from 
step 2 and incubated at 37℃ at 250rpm for 2-3 hours. Optical density (OD) was monitored 
regularly using a spectrophotometer until it reached 0.4-0.5. After the desired OD was reached, 
the culture was transferred into large volume centrifuge bottles (sterile and pre-chilled) in a 
sterile laminar hood (250ml/bottle).  Centrifugation was carried out at 4500rpm for 15 min at 
4℃. The supernatant was discarded aseptically in a sterile laminar hood). To the 250ml 
harvested cell pellet, 25ml of sterile 0.1M CaCl2 was added and mixed by gently pipetting up and 
down on ice. The mixture was shifted to sterile and pre-chilled 50ml falcon tubes. Incubation 
was carried on ice for 15 min. Centrifugation was carried out at 4℃ for 15 min at 4500rpm. 
Supernatant was then discarded aseptically. 2ml of pre-chilled 0.1M CaCl2 containing 30% 
Glycerol was added to each of the pellets obtained and cells were delicately mixed by pipetting 
on ice. The tubes were placed on ice. 100ul of cells were aliquoted in sterile pre-chilled 
eppendorf tubes and cells were shifted at -80℃. 
2. Ampicillin Preparation 
50mg/ml stock solution of Ampicillin was prepared by dissolving 0.5g of Ampicillin salt 
in 10ml ddH2O and filter sterilized using 0.2 um filter. 1ml aliquots were saved at -20℃. 
Working concentration of Ampicillin used was 50ug/ml. 
3. Isopropyl B-D-1-thiogalactopyranoside (IPTG) Preparation 
1M IPTG was prepared by dissolving 1g of IPTG in 5ml distilled, di-ionized water 
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(ddH2O) and filter sterilized using 0.2 um filter. Figure B1 shows the structure of IPTG. IPTG 
activates the lac operon induces protein expression.  
 
4. Cloning 
pET22b(+) Vector map and details are in Figure B2. pET22b(+) plasmid was provided. 
1ul was transformed into DH5𝛼 cells and plated on Agar plates containing 50ug/ml Ampicillin 
selection. Rub-FGF1-pET22b(+) clone was provided and transformed into DH5𝛼 cells and 
plated on Ampicillin Agar plates. Colonies were picked and plasmid isolation was carried out. 
5. Digestion 
Digestion was set up as shown in Table B1. 50ul digestion mixtures were put in the 
thermocycler and incubated at 37℃ for 16 hours. 1% agarose gel was prepared in 1X TAE. A 
preliminary gel was run for the digestion mixtures by loading 4ul of the digested and undigested 
samples for 30min at 120V in fresh 1X TAE. After confirming that the digestion was complete, 
the entire remaining digested samples were loaded onto fresh prepared 1% gel and gel run for 
40min at 120V.  
6. Antarctic Phosphatase Treatment 
Antarctic phosphatase treatment was carried out for pET22b before the gel for excision 
Figure B1. Structure 
of Isopropyl B-D-1-
thiogalactopyranoside 
(IPTG) 
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was run, by adding 0.5ul Antarctic phosphatase (AP) enzyme and 5ul AP buffer and sample was 
incubated in the thermocycler (AP program: 37℃ 15 min and 65℃ 5 min).   
 
7. Gel Extraction and Elution 
Gel excision was carried out under the UV with blade. In case of pET22b(+)-Rub-FGF1 
digestion, lower band corresponding to 300bp was excised. The gels were put in respective 
labeled eppendorfs (weight pre-measured). This step was carried out carefully with minimum 
UV exposure to the DNA. Gloves were worn at all times when dealing with ethidium bromide. 
The gel weights were measured. Table B2 shows the respective weights of the gels.  
Elution was carried out using QIAgen Gel Extraction Kit. 3 volumes of QG buffer were 
added to 1 volume of the gel (100mg~100ul). Incubation was carried out at 50℃ for 10 min with 
vortexing every 2-3 min until the gel completely dissolved. 1gel volume isopropanol was added. 
The sample was added to QIAquick spin column (in a 2ml collection tube) and centrifugation 
Figure B2. pET22b(+)(+) Vector Map. pET22b(+)(+) was used 
as a vector for cloning. The gene of interest (Rub-FGF1) was 
cloned between NdeI and EcoRI sites.  
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was carried out for 3 min at 13000 rpm. Flow through was discarded. 0.75ml PE (Wash Buffer) 
was added and centrifugation was carried out at 13000rpm for 3min.  QIAquick column was 
placed in a new 1.5ml eppendorf tube. Elution was carried out in 20ul EB (Elution Buffer). 2ul 
sample of the elution was run and concentration was determined using NanoDrop. The 
concentrations are as follows: 
Rub-FGF1: 14.3ng/ul 
pET22b(+): 12.4 ng/ul 
Table B1. Digestion 
Ingredients Vector-pET22b(+) Clone-Rub-FGF1-
pET22b(+) 
Cut-Smart Buffer 5ul 5ul 
pET22b(+) 42.5ul - 
Rub-FGF1-pET22b(+) - 42.5ul 
EcoRI 1ul 1ul 
NdeI 1ul 1ul 
BSA 0.5 0.5 
MQ-Water - - 
Total 50ul 50ul 
 
Table B2.  
 Empty eppendorf (g) Eppendorf + Gel (g) Gel (g) 
pET22b 0.99 1.29 0.03 
pET22b-Rub-FGF1 0.99 1.41 0.042 
 
8. Ligation 
Ligation was set up as shown in Table B3. 
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Mixtures were incubated in thermocycler in LIGA program (16℃ overnight). 
Table B3. Ligation 
 1:3 (ul) 1:5 (ul) Control (ul) 
Plasmid (pET22b) 3 2 3 
Insert (Rub-FGF1) 5 6 - 
10X Ligation Buffer 1 1 1 
Ligase 1 1 1 
ddH2O - - 5 
Total 10 10 10 
 
9. Transformation 
5ul ligation mixtures were transformed into DH5𝛼 competent cells. Incubation was 
carried out on ice for 15-20min. The cells were heat-shocked at 42℃ for 60 seconds and 
immediately shifted to ice. 400ul sterile LB media was added and mixtures incubated at 37℃ for 
30-45 min. 100ul mixtures were plated on separate labeled Ampicillin Agar plates and incubated 
overnight (12-14 hours) at 37℃. 
10. Plasmid DNA Isolation 
5-7ml bacterial culture was inoculated overnight from the colonies in the positive plates. 
Cells were harvested by centrifugation at 6000rpm for 15 min and supernatant was discarded.  
The bacterial pellets were re-suspended in 250ul Buffer P1 (Re-suspension buffer containing 
RNase A) and transferred to a micro-centrifuge tube. 250ul of Buffer P2 (Lysis Buffer) was 
added and mixed by inverting the tubes 4-6 times. The optimal lysis time is 3-5 min after which 
the solution gets viscous. 350ul of Buffer N3 (Neutralization Buffer) was added and tubes 
inverted 4-6 times to ensure mixing. Centrifugation was carried out at 13000rpm for 10min. The 
supernatant from step 4 was carefully applied to QIAprep spin column by pipette, making sure 
 27 
 
not to disturb the pellet. Centrifugation was carried out at 13000rpm for 1min and flow-through 
was discarded. QIAprep spin column was washed by adding 0.75 ml PE (Wash Buffer) and 
centrifugation was carried out for 1 min. Flow through was discarded and centrifugation was 
carried out for an additional minute to remove residual wash buffer. The QIAprep column was 
placed in a clean 1.5ml microcentrifuge tube. DNA was eluted by adding 25-30ul Buffer EB 
(10mM Tris.Cl, pH8.5) to the center of the column. The column was left at room temperature for 
1-2 min and then centrifugation was carried out for 1 min.  
After Plasmid Isolation, digestion was set up using the same enzymes EcoRI and NdeI to 
confirm successful cloning.  
11. Small-Scale Expression (SSE) 
Small-scale expression of Rub-FGF1 was performed to verify the absence of fusion 
protein in BL21 (DE3) cells and ability of these cells to produce the desired protein in the 
presence of the inducer. 5ml Terrific Broth (TB) was inoculated using glycerol stocks for Rub-
FGF1, using 5ul of 50mg/ml Ampicillin selection and incubated at 37C overnight 12-14 hours. 
This was the primary culture. After 12-14 hours of incubation, 50ml of TB was inoculated with 
5ml of the primary culture using 50uL of 50mg/ml Ampicillin and incubated further for 2 hours. 
Optical density was then checked using UV-visible spectroscopy at a wavelength of 600nm. The 
blank used was sterile TB. The induction is supposed to be carried out in the log phase, where 
the bacteria are growing at an exponential rate. The OD at that instant is 0.4-0.6. The OD was 
0.547. 1ml sample was saved as Pre-Induced sample to be run on the SDS-PAGE gel.  
The secondary culture was then induced using 1M IPTG; 50ul 1M IPTG was added to the 
culture and cells were incubated for 4 hours at 37C. After four hours, 1ml sample was saved as 
Post-Induced sample to be run on the SDS-PAGE gel. The cells were then harvested by 
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centrifuging them for 10 minutes at 6000rpm, 4C and supernatant was discarded. The cells were 
washed with 1X Phosphate buffer saline (PBS), pH 7.2. The cells were re-suspended in 15ml 1X 
PBS pH 7.2.  
Ultra-sonication was carried out at power 5, 10 pulses on, 10 pulses off for 15 minutes, 
with 5 min break in-between. This was done to lyse the cells by releasing the cytosol content into 
the solution. Centrifugation is then carried out at 19000rpm for 30 min at 4C. The cell debris is 
then separated from the solution that contains the protein of interest. The supernatant, which 
contains the protein of interest, is transferred to a new falcon. 1ml of supernatant sample is taken 
to run on the gel. A smear of the pellet is also taken to run the gel. 
Samples for SDS-PAGE were prepared. Pre-Induced and Post-Induced samples were 
centrifuged at 6000 rpm for 5 min and supernatants were discarded. 
12. Trichloroacetic acid Precipitation (TCA prep)  
100ul of 100% Trichloroacetic acid (10% TCA) was added to 1ml sample of the 
supernatant saved after high-speed centrifugation. The mixture was vortexed and centrifuged at 
13000 rpm for 3 min. Supernatant was discarded. 1ml acetone was added to the pellet and pellet 
mixed by vortexing. Centrifugation was carried out again at 13000 rpm for 3 min and 
supernatant discarded again. The sample was air-dried. 
To all the four samples: Pre-Induced, Post-Induced, Supernatant and Pellet, 30ul 8M 
Urea and 15uL Loading dye was added and sample pellets re-suspended. The samples were 
boiled at 95℃ for 3-5 min and were then loaded onto the SDS gel.  
13. Sodium-Dodecyl Sulfate-Polyacrylamide Agarose Gel Electrophoresis (SDS-PAGE) 
15% Resolving gel and stacking gel were prepared as shown in Table B4. The gel was 
run at 200V, 100mA for 50 min. After gel running was complete, the gel was stained in 
 29 
 
Coomassie Blue for 3-5 min, gently rinsed with water and put in the de-staining solution 
overnight with 2 KimWipes overlaid at the top. The gel was scanned the next day.  
14. Large-Scale Expression (LSE) 
Large-Scale Expression was performed to generate large quantities of Rub-FGF1 protein 
so that it can be purified for characterization studies. The protocol is exactly similar to SSE, 
except 150ml of primary culture was inoculated, and 3 liters of secondary culture was inoculated 
using 25ml of the inoculated and overnight incubated primary culture. Appropriate amounts of 
50mg/ml ampicillin and 1M IPTG were added. From the 3 liters culture volumes, 3 falcons 
containing 1liter pellets were obtained and were saved at -20C. They were dissolved in 25ml 
1XPBS pH 7.2 for ultra-sonication and further processing. Samples were collected at each stage 
to run them on SDS-PAGE. 
15. Purification 
The pellet obtained from LSE was dissolved in 25 of 1X PBS pH 7.2. Ultra-sonication 
was performed to lyse the cells and the lysate was separated from the cell debris by 
centrifugation at 19000 rpm for 30 min at 4C. The supernatant was transferred to a new falcon to 
be loaded onto the column. 
Ni+-NTA column was used for purification since the vector pET22b-Rub-FGF1 has a 
His-tag at the N-terminal of the protein of interest. The column was pre-equilibrated with 2 
column volumes (30ml) of 1X PBS pH 7.2. The supernatant was then loaded onto the column 
and if peak was observed, then the flow-through was collected. The peak was then base-lined 
with 1X PBS pH 7.2. 50ml of the following solutions were prepared immediately before they 
were loaded onto the column and peaks were collected and labeled. The solutions were made up 
to 50ml with ddH2O.  
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Table B4. 
 15 % Resolving Gel (2 gels) Stacking Gel (2 gels) 
ddH2O 1.1 ml 3.75 ml 
30% Acrylamide 5 ml 0.83 ml 
1M Tris.HCl pH 8.8 3.75 ml - 
1M Tris.HCl pH 6.8 - 0.62 ml 
10% SDS 100 uL 50 uL 
10% APS 100 uL 50 uL 
TEMED 10 uL 8 uL 
 
The column was regenerated using two column volumes of 8M Urea (fraction collected), 
five-column volumes of Milli-Q water and two-columns volumes of 20% ethanol. The column 
was saved at -20C. TCA precipitation was carried out on 200uL of all the samples collected 
(flow-through, 20mM, 50mM, 100mM, 250mM and 500mM IMD eluants, 8M urea) and 
samples were prepared to be run on SDS-PAGE. The purity of the protein was verified by a 
distinct band at ~10-kDa. The pure protein was collected at 250mM IMD fraction.  
16. Concentration and Heat Treatment 
The pure protein fraction collected at 250mM IMD was buffer exchanged with 1X PBS 
pH 7.2 and concentrated using amicon (Millipore centrifugal concentrator) with a 3-kDa 
molecular weight cut-off. The concentration of the protein was measured using a NanoDrop at 
280nm. After concentration, the purified sample was subjected to heat treatment at 75℃ for 
10min. The sample was immediately placed on ice. Centrifugation was then carried out at 13K 
for 3 min. After centrifugation the supernatant was transferred to a new eppendorf. 30ul of the 
supernatant was prepared for running on the gel. The pellet was also processed for SDS-PAGE. 
Figure B3 describes the steps used in obtaining compact band. 
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Table B5. 
 4M Imidazole (IMD) 10X PBS 
20mM IMD 250 uL 5 ml 
50mM IMD 625 uL 5 ml 
100mM IMD 1250 uL 5 ml 
250mM IMD 3250 uL 5 ml 
500mM IMD 6250 uL 5 ml 
 
17. Thrombin Cleavage 
Depending on the concentration of the heat-treated purified supernatant (determined 
using NanoDrop at 280nm), thrombin cleavage was set up at room temperature for 1ml of the 
sample and incubated for 48 hours. After incubation period was over, the sample was heat-
treated at 75℃ for 10min and centrifugation was carried out at 13K for 3 min. Supernatant was 
transferred to new eppendorf and 30ul sample was taken for SDS-PAGE (Sample B). The pellet 
was also processed (Sample A). 7.5% TCA prep was carried out on the supernatant and the 
mixture was spun at 13K for 3 min. The supernatant was transferred to fresh eppendorf. The 
pellet obtained was dissolved in 1ml 1X PBS pH 7.2 and 30ul was taken for SDS-PAGE 
(Sample C). The supernatant was neutralized using concentrated sodium hydroxide (NaOH) and 
heat-treated again at 75℃ for 10min. Centrifugation was carried out at 13K for 3 min and 
supernatant transferred to new eppendorf. Heat-treated pellet post-TCA prep was also processed 
for running on the gel (Sample D). 30ul of the supernatant was taken for gel too (Sample E). The 
rest of the supernatant was saved for analysis by mass spectrometry, Circular Dichroism (CD) 
and Fluorescence.  
Samples A-E were processed by adding 30ul 8M Urea and 15ul Loading Dye and boiled 
at 95℃ for 3-5min. 15ul samples were loaded onto the gel. The flow-chart Figure B4 
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summarizes the steps followed to obtain the pure FGF1 peptide. 
 
18. Far UV Circular Dichroism Spectroscopy 
The CD spectra were collected on a Jasco 1500 spectropolarimeter in order to analyze the 
secondary structure of heparin-binding region of FGF1. A 200ul fraction of the sample was 
placed in 0.2 cm path length quartz cell. Temperature of the samples was maintained to 25℃. 
Data were scanned from 190nm to 250nm at a rate of 50nm/min. The scan speed used was 
50nm/min and 5 iterations were carried out. Air blank (empty dry cuvette) was done under 300 
volts. 1X PBS was used as a blank. The peptide (FGF1) sample was then run. Once the data was 
collected, it was smoothened using Schvitzky-Golay smoothing algorithm and the buffer signal 
was subtracted. CD data were transformed into molar ellipticity in the units of degree.cm2/dm of 
monomer subunits.  
 
 
Figure B4. Flow Chart of the Steps followed for the processing 
of thrombin cleaved sample to obtain pure FGF1 peptide.  
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19. Intrinsic Fluorescence Spectroscopy 
Fluorescence emission spectrum of FGF1 peptide was performed using Hitachi F-2500 
spectrofluorometer at 25℃, in a single beam mode. The sample for this experiment was prepared 
using a protein concentration of 0.87 mg/ml in 1X PBS (pH 7.2). The sample was excited at a 
wavelength of 280nm, and the data was collected between 300nm and 450nm in order to analyze 
the fluorescence of tryptophan at 350nm.  
20. Mass Spectrometry 
20ul of the pure FGF1 peptide obtained by thrombin cleavage was sent to facility in 
Chemistry/Biochemistry Department. Figure B5 represents the steps involved in obtaining mass 
spectrum.  
 
Rub-FGF1 was separated by means of an SDS gel and then it was subjected to proteolytic 
cleavage by thrombin that will result in Rub and FGF1 peptides. The resulting peptides can 
either be separated by an HPLC or in our case, 7.5% TCA precipitation resulted in pure FGF1 
peptide in the supernatant. The peptide was then sent for mass spectrometry. The peptides are 
ionized before mass spectrometry (Steen & Mann, 2004). The spectrum obtained is then 
analyzed. 
  
Figure B5. Mass Spectrometry Pipeline. (Steen & Mann, 2004)  
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C. RESULTS AND DISCUSSION 
1. Cloning of Rub-FGF1 
 pET22b(+) was used as a vector for cloning. EcoRI and NdeI restriction sites were 
chosen and the plasmid was digested with these enzymes according to digestion protocol 
mentioned in materials and methods. pET22b(+) is a 5493bp vector with EcoRI and NdeI 
restriction sites present at 192bp and 288bp, respectively. Digestion with these two enzymes 
results in the release of a 96bp band, which is too faint to be observed in a 1% agarose gel. 
Digestion of pET22b(+) using EcoRI and NdeI is shown in the Figure C1. Digestion results in 
linearizing pET22b(+) vector generating ~5kb linear plasmid as shown in lanes 2 and 3. 
Undigested pET22b(+) is shown in lane 1. Since the plasmid is circular, supercoiled and 
compact, it travels faster as compared to a linear plasmid of the same size and therefore uncut 
pET22b(+) is observed at ~3-3.5kb. The digested pET22b(+) bands were excised for further 
experiments.  
 
Figure C1.  Digestion of pET22b(+) vector using the enzymes EcoRI 
and NdeI. The lanes correspond to pET22b(+) Uncut (Lane-1), 
pET22b(+) Cut (Lanes-2 and 3) and 1kb DNA ladder (Lane-4).  
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Rub-FGF1-pET22b(+) was provided. Rub-FGF1-pET22b(+) is ~5700bp. Digestion of 
Rub-FGF1-pET22b(+) with EcoRI and NdeI is shown in the Figure C2. After digestion with 
EcoRI and NdeI, 270bp of Rub-FGF1 is released as shown in Figure C2. The 270bp Rub-FGF1 
band was excised for further cloning experiments.  
 
Antarctic phosphatase treatment was carried out for pET22b(+) vector alone before the 
digestion gels were run. Antarctic phosphatase is thermostable alkaline phosphatase and is 
purified from a recombinant source. It non-specifically catalyzes the dephosphorylating of the 5’ 
and 3’ ends of the DNA sticky phospho-ends generated after digestion. It also acts on the blunt 
ends generated from some restriction enzymes. It is commonly used in molecular biology and we 
used to dephosphorylate the vector at both ends to prevent relegation of the linearized pET22b 
(+) generated after digestion.  
The respective gel bands for pET22b(+) Cut and Rub-FGF1 (lower bands) were then 
excised and gel extraction was carried out using the protocol mentioned in Materials and 
Figure C2.  Digestion of Rub-FGF1-pET22b(+) plasmid using the 
enzymes EcoRI and NdeI. The lanes correspond to 1kb DNA ladder 
(Lane-1), Plasmid Uncut (Lane-2) and Plasmid Cut (Lanes-3 and 4).  
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Methods section. The elution gel is shown in Figure C3.  
 
The concentrations were determined, and ligations were set up as mentioned in Materials 
and Methods. Colonies were observed in both positive 1:3 and 1:5 ligation plates. 2 colonies 
from both plates were picked and LB was inoculated for plasmid isolation. Digestion 
confirmation was then carried out with the same enzymes used for initial digestions: EcoRI and 
NdeI. Figure C4 represents the digestion of 2 plasmids (Rub-FGF1-pET22b(+)). The digestion 
confirmed that the colonies picked were positive and the plasmid pET22b(+) carried the gene of 
interest Rub-FGF1, consistent with a 270bp Rub-FGF1 band and ~5300bp Cut pET22b(+) as 
shown in Figure C4.  
2. Small-Scale Expression 
Small-scale expression of Rub-FGF1 was carried out after digestion confirmation. The 
Figure C3.  Elution of excised pET22b(+) Cut and Rub-
FGF1. The lanes correspond to Rub-FGF1 (Lane-1) and 
1kb DNA ladder (Lane-2) and pET22b(+) Cut (Lane-3).  
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SDS-PAGE for small-scale expression of Rub-FGF1-pET22b(+) is shown in the Figure C5.  
 
Rub-FGF1 is a 90 amino-acids long protein with a size of almost 10kDa. Lane 2 in 
Figure C5 shows pre-induced sample and has no protein of interest. Lane 3 is the post-induced 
sample and contains the protein of interest Rub-FGF1. Lane 4 and 5 are pellet and supernatants, 
respectively obtained after sonication of the cell pellet. Sonication alone was sufficient to get the 
recombinant protein in the cell lysate and no additional lysis buffers and agents were required. 
Lane 4 does not contain any protein of interest, which shows that the lysis of the cells was 
complete. Lane 5 shows the presence of Rub-FGF1 (boxed). This shows that the expression of 
Rub-FGF1 did take place after cells were induced with IPTG. The same-sized Rub-FGF1 is also 
present in Lane 3 (post-induced sample). The gel, however, ran a bit slant and therefore the band 
in this lane appears slightly above than in lane 5.  
3. Purification of Rub-FGF1: 
Figure C6 is the SDS-PAGE analysis of the purification of Rub-FGF1. The expression 
Figure C4.  Digestion Confirmation of Rub-
FGF1-pET22b(+) plasmid using the enzymes 
EcoRI and NdeI. The lanes correspond to 1kb 
DNA ladder (Lane-1), Plasmid Uncut (Lane-
2) and Plasmid Cut (Lanes-3 and 4).  
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and purification of Rub-FGF1 was observed at both 100mM IMD and 250mM IMD with thick 
compact bands observed at around 10-kDa, consistent with the size of the fusion protein Rub-
FGF1 (9.9-kDa).   
 
Ni+-NTA column was used for purification. pET22b(+) has a Histidine tag coding 
sequence from 140-157bp in the vector as shown in Figure B2. The poly-histidine tag generates a 
string of histidine residues (6-10) either at the N-terminus or the C-terminus of the recombinant 
protein after induction with IPTG; in this case it generates hexa-histidine tag located at the N-
term of the recombinant protein. 
This purification technique is an example of immobilized metal affinity chromatography. 
The Histidines bind to the Nickel in the column. Nickel is the transition metal that is 
immobilized on the resin matrix. Cobalt, copper and zinc are examples of other transition metal 
 1               2                 3                  4                 5 
 
Figure C5.  Small-scale expression of Rub-FGF1-
pET22b(+) in BL21 (DE3) cells. The lanes correspond to In-
house Protein marker (Lane-1), Pre-Induced (Lane-2), Post-
Induced (Lane-2), Pellet (Lane-4) and Supernatant (Lane-5).  
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ions used for his-tagged recombinant protein purifications. Nickel is most commonly used 
because it gives high yield. His-tags gave a high affinity for nickel ions and bind to the matrix 
tightly. The other proteins that are present in the cell lysate either bind weakly to the column or 
do not bind at all. This way pure recombinant proteins are obtained from crude cell lysates.  
 
The pure recombinant protein in this case Rub-FGF1 is eluted using different 
concentrations of imidazole (IMD). Imidazole competes with the his-tag for binding to the Ni+-
charged column. A range of low to high concentrations of imidazole is added. Proteins that bind 
weakly typically elute at lower concentrations of imidazole (20mM and 50mM IMD), where as 
His-tagged proteins are eluted at higher concentrations of imidazole (100mM and 250mM IMD). 
Figure C6. SDS-PAGE analysis of a purification of Rub-FGF1. The lanes 
correspond to Pellet (Lane-1), Supernatant (Lane-2), Flow-through (Lane-
3), 20mM IMD (Lane-4), 50mM IMD (Lane-5), 100mM IMD (Lane-6), 
250mM IMD (Lane-7), 500mM IMD (Lane-8) and Urea (Lane-9). The gel 
results show the successful expression and purification of Rub-FGF1 fusion 
protein corresponding to thick compact bands in lane-6 and 7 (boxed) at 
100mM IMD and 250mM IMD, respectively.  
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If the his-tag is longer, a higher concentration of imidazole is required to elute bound proteins 
from the column. Using longer his-tags typically helps when there are more non-recombinant 
proteins present, especially if the recombinant protein is from a eukaryotic source.  
The pH of the buffer used to prepare imidazole for elution was set at 7.2 (10X Phosphate 
Buffer Saline (PBS)), since it is consistent with the physiological pH. I used an established 
purification protocol in Kumar’s lab and obtained pure compact protein at pH 7.2 and did not 
have to optimize my purification at different pHs.  
 
Since my recombinant protein had a Rubredoxin upstream of the C-terminal heparin 
binding peptide of FGF1, purification was easy. Rubredoxin, a stable protein, provided a direct 
read-out of the expression and elution of the protein because of its red color. The recombinant 
protein could be seen eluting through the column. A lower flow-rate of 2ml/min was used to 
Figure C7. Ni+-NTA metal affinity purification setup. Rubredoxin provides 
a direct read-out for the expression and elution of the recombinant protein 
Rub-FGF1. The red color on the column is because of Rubredoxin.  
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achieve efficient elution of the recombinant protein. Figure C7 shows the purification setup and 
red color of the protein on the Ni+-NTA column.  
4. Concentration and Heat Treatment 
Figure C8 shows the results of protein concentration of the 250mM IMD fraction 
collected during purification. The fraction was concentrated to 5 ml with buffer exchange (1X 
PBS pH 7.2). Comparing lanes 2 and 3 in Figure C8 shows Rub-FGF1 concentration (boxed) 
pre- and post-concentration. A thicker, more compact Rub-FGF1 band is obtained as shown in 
Lane 3.  
 
Amicon Ultra Centrifugal filter was used to concentrate the recombinant protein. 
Through ultrafiltration, fast sample processing and efficient concentration of Rub-FGF1 was 
obtained for downstream experiments.  
The SDS-PAGE for heat-treated concentrated sample is shown in Figure C9. The 
Figure C8. Concentration of purified 
Rub-FGF1. The lanes correspond to In-
house Protein marker (Lane-1), Purified 
250mM IMD fraction (Lane-2), 
Concentrated 250mM IMD purified 
sample (Lane-3).  
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objective of heat treatment was to obtain a pure compact band of Rub-FGF1 before using the 
sample for further experiments. As shown in the figure lane 3, post-heat treatment, most of the 
impurities in the 250mM IMD are left in the pellet. The pellet contains all the contaminants that 
are not resistant to heat. Rubredoxin-tagged recombinant protein however is thermostable and 
can be seen as a single pure band in the supernatant in lane 4.  
 
5, Thrombin Cleavage 
The concentrated heat-treated pure 250mM IMD sample was cleaved by thrombin and 
processed.  Thrombin cleaves at LVPR-GS at the junction of Rubredoxin and FGF1 C-terminal 
peptide. Lane 3 in Figure C10 represents the complete cleavage of Rub-FGF1 fused protein into 
Rub (7.15-kDa)  and FGF1 peptide (2.75-kDa). After several optimizations for TCA preps, we 
were able to obtain pure FGF1 peptide with 7.5 % TCA prep as shown in Lane 6 in Figure C10.  
TCA precipitation is a technique used for concentrating protein solutions and 
Figure C9. Heat Treatment of Purified, 
Concentrated 250mM IMD fraction. The 
lanes correspond to concentrated sample 
(Lane-1: same as Lane-3 in Figure C8.), 
Protein marker (Lane-2), Pellet (Lane-3) 
and Supernatant (Lane-4).  
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simultaneously removes contaminating substances. 7.5% TCA precipitation was carried out on 
the thrombin cleaved Rub-FGF1 in order to get rid of Rubredoxin which stays in the pellet after 
TCA precipitation as shown in lane 5 of Figure C10.  
The pure peptide was further characterized by mass spectrometry, analysis by circular 
dichroism (CD) and Fluorescence.  
 
6. Circular Dichroism Spectroscopy 
The CD spectrum in Figure C11 shows (based on comparison with standard curves) that 
FGF1 peptide is an 𝛼 helix with positive peak at 190 nm and minima at 208 and 222 nm. 
According to literature, if the second minima (222nm) are shallower, the 𝛼 helix has increasing 
amounts of random coil, which is shown in my data. 
Figure C10. Thrombin Cleavage. The lanes correspond 
to Concentrated heat treated purified protein-2.69mg/ml 
(Lane-1), Direct thrombin cleavage pellet after heat 
treatment (Lane-2), Direct thrombin cleavage 
supernatant after heat treatment (Lane-3), 7.5% TCA 
prep-pellet dissolved in 1X PBS pH 7.2 (Lane-4), 7.5% 
TCA prep-supernatant 1ml heat treated-pellet (Lane-5), 
7.5% TCA prep-supernatant 1ml heat treated-
supernatant (Lane-6). 
 44 
 
Circular Dichroism (CD) is a technique employed to determine the secondary structure of 
proteins. Different structural elements have characteristic CD spectra. It is due to the 
chromophores of the amides of the polypeptide backbones of proteins being aligned in arrays and 
shift in their optical transitions (Greenfield, 2006). 𝛼-helical proteins have minima at 222nm and 
208nm and a positive maximum at 195nm (Greenfield, 2006). 𝛽-pleated sheets have a minimum 
at 218nm and a maximum at 195nm (Greenfield, 2006).  
In order to determine the secondary structure of protein, the protein sample needs to at 
least 95% pure and the protein concentration may range from 0.005 to 5mg/ml (Greenfield, 
2006). This can be obtained by HPLC or gel electrophoresis (Greenfield, 2006). Although CD 
doesn’t provide secondary structure of specific residues as X-ray crystallography and NMR, it is 
advantageous because it allows data collection and analysis in less time with protein samples 
having concentrations as less as 20𝜇g in aqueous buffers under physiological conditions 
(Greenfield, 2006).  
 
Figure C11. Circular Dichroism. CD spectrum of 
0.87mg/ml FGF1 peptide reveals that it’s a random 
coil.    
 
 45 
 
7. Fluorescence 
The fluorescence spectrum is in the range from 300-450 nm as shown in Figure C12. The 
excitation was set at 280nm. The emission wavelength as observed from the spectrum is at 
350nm consistent with the presence of tryptophan in the heparin-binding pocket of FGF1.  
 
8. Mass spectrometry 
The mass spectrum shown in Figure C13 was obtained for the peptide shown in Lane 6 
Figure C10. The black-circled part highlights the molecular weight of the heparin binding 
peptide of FGF1 consistent with the size of 2.75 kDa. There are a lot of other peaks observed in 
the spectrum and since we didn’t analyze it so we cannot say for sure, but it might correspond to 
thrombin enzyme utilized to cleave Rub-FGF1.  
 
 
Figure C12. Fluorescence emission spectrum of heparin 
binding pocket of FGF1. Protein (0.87mg/ml) was in 1X 
PBS pH 7.2. The excitation wavelength was 280nm and the 
emission wavelength as observed is at 350nm.  
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9. Sequence Information 
NNNNNGAGCCGGTACAATTCCCCTCTAGAAATAATTTTGTTTAACTTTAAGAAGGAG
ATATACATATGCACCACCACCACCACCACATGGCGAAATGGGTTTGCAAGATTTGCG 
GCTATATTTACGACGAAGATGCTGGCGACCCGGACAACGGCATTAGTCCGGGCACC
AAATTTGAAGAACTGCCGGATGACTGGGTCTGCCCGATCTGTGGTGCGCCGAAAAG
CGAATTTGAAAAGCTGGAAGATCTGGTGCCGCGTGGATCCAACTGGTTCGTTGGTCT
GAAGAAAAACGGTTCGTGTAAACGCGGTCCGCGCACCCACTACGGTCAAAAATGAG
AATTCGAGCTCCGTCGACAAGCTTGCGGCCGCACTGGAGCACCACCACCACCACCA
CTGAGATCCGGCTGGTAACAAAGCCCGAAAGGAAGCTGGGTCGGCC 
 
 
Figure C13. Mass Spectrometry Analysis of Heparin-Binding Peptide of 
FGF1. The circled part represents the molecular mass of heparin-binding 
peptide of FGF1 of 2.75-kDa. 
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The sequence of Rub-FGF1 fusion protein is as follows: 
Rub-FGF1 
MHHHHHHMAKWVCKICGYIYDEDAGDPDNGISPGTKFEELPDDWVCPICGAPKSEFEK
LEDLVPRGSNWFVGLKKNGSCKRGPRTHYGQK 
Rub protein 
MHHHHHHMAKWVCKICGYIYDEDAGDPDNGISPGTKFEELPDDWVCPICGAPKSEFEK
LEDLVPR 
FGF1 peptide 
GSNWFVGLKKNGSCKRGPRTHYGQK 
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D. CONCLUSION 
Several rounds of Ni+-NTA purification of Rub-FGF1 resulted in stable Rub-FGF1 protein 
categorized by red color of Rubredoxin in solution. Heat-treatment to get rid of impurities 
showed that the fusion protein is stable to thermal degradation. Subjecting the fusion protein to 
cleavage by thrombin resulted in the separation of Rubredoxin and the heparin binding C-
terminal pocket of FGF1. The important aspect of this project required obtaining pure heparin-
binding C-terminal part of FGF1 and characterizing it. The heparin-binding part was successfully 
obtained by 7.5% TCA precipitation. HPLC was another technique to separate Rubredoxin and 
FGF1 post-thrombin cleavage (cleaves at LVPR-GS).  
Circular Dichroism Spectroscopy of the heparin-binding peptide of FGF1 (25 amino acids 
long) showed increasing amount of random coil because of the shallow minima observed at 222 
nm. Fluorescence spectroscopy data showed a maximum at 350nm consistent with the presence 
of tryptophan in the heparin-binding peptide of FGF1. A slight peak is observed at 308nm but it 
is not pronounced, however, its observation is consistent with the presence of tyrosine in the 
heparin-binding peptide of FGF1. 
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